OTC Cold-and-Cough Label Centers on a Three-Drug Symptom Strategy
The updated DailyMed label for COLD AND COUGH lays out a familiar but clinically consequential combination: brompheniramine maleate, dextromethorphan hydrobromide, and phenylephrine hydrochloride. Each 10 mL delivers 2 mg of brompheniramine, 10 mg of dextromethorphan, and 5 mg of phenylephrine, positioning the product as a multi-symptom oral solution for upper respiratory complaints rather than a single-target remedy. The label classifies it as a human OTC drug under an OTC monograph, with oral administration and no DEA schedule. Packager information identifies H E B, and the product is tied to NDC 37808-987-26.
The pharmacology is straightforward, but the bedside implications are not. Brompheniramine blocks histamine-mediated symptoms such as rhinorrhea, sneezing, and itchy watery eyes; dextromethorphan suppresses cough; phenylephrine is intended to relieve nasal congestion by vasoconstriction in the nasal mucosa. In practice, the product is built to blunt the cluster of cold and allergy symptoms that often drive self-treatment, especially when a cough, a runny nose, and congested breathing appear together.
What the Label Says the Product Is For
The labeled uses are limited to temporary relief of cough due to minor throat and bronchial irritation associated with a cold, and nasal congestion related to the common cold, hay fever, or other upper respiratory allergies. The same formulation is also presented for hay fever symptoms, including runny nose, sneezing, itchy watery eyes, and itching of the nose or throat. A key claim is that it temporarily restores freer breathing through the nose.
That therapeutic scope matters because the product is not designed for chronic lower-airway disease or for cough that persists beyond a typical self-limited viral illness. The label draws a clear line between upper-respiratory symptom palliation and the warning signs of a more serious process. Cough with substantial phlegm, chronic cough linked to smoking, asthma, emphysema, or chronic bronchitis, and respiratory disease with ongoing symptoms are all reasons to seek clinician input before using the product.
Safety Warnings Target Common OTC Misuse
The strongest contraindication is use with a prescription monoamine oxidase inhibitor, or within 2 weeks of stopping one. That warning is clinically important because dextromethorphan and phenylephrine can interact with MAOI therapy in ways that raise the risk of adverse neuropsychiatric or cardiovascular effects. The label also says not to use the product to make a child sleepy, a warning that reflects the historical misuse of antihistamine-containing cold remedies for sedation rather than symptom control.
Several precautions focus on populations where even routine OTC ingredients can cause disproportionate harm. Patients with heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or trouble urinating because of an enlarged prostate gland are instructed to ask a doctor before use. Sedatives and tranquilizers are another concern, since the product may cause marked drowsiness and alcohol can amplify that effect. In children, excitability may occur instead of sedation, a reminder that first-generation antihistamines can produce paradoxical central nervous system stimulation.
The label also instructs users to stop the product and seek medical advice if nervousness, dizziness, or sleeplessness develops. Persistent or worsening symptoms trigger a separate warning: if symptoms do not improve within 7 days or are accompanied by fever, the user should stop and consult a clinician. Cough lasting more than 7 days, recurring cough, or cough accompanied by fever, rash, or persistent headache also warrants medical evaluation, and the label explicitly states that a persistent cough may be a sign of a serious condition.
Dosing Limits Narrow the Margin for Error
The dose instructions are precise. Adults and children 12 years and over should take 20 mL every 4 hours. Children 6 to under 12 years should take 10 mL every 4 hours. Children under 6 years should not use the product. No more than 6 doses should be taken in any 24-hour period, and the dose should be measured only with the supplied cup.
Those limits are not cosmetic. They are the guardrails that keep a three-ingredient cough-and-cold combination from drifting into overdosing, especially in households where more than one remedy may be used at the same time. Because the formulation includes a sedating antihistamine and a sympathomimetic decongestant, overuse can shift quickly from symptom relief to unwanted central nervous system and cardiovascular effects. The age cutoff is equally direct: this is not a children’s product for toddlers, and the label makes that restriction explicit.
A brief line in the storage section adds another practical point: each 10 mL contains sodium 4 mg, and storage should remain at 20°–25°C, or 68°–77°F. The inactive ingredients include anhydrous citric acid, edetate disodium, FD&C Blue No. 1, FD&C Red No. 40, flavor, glycerin, propylene glycol, purified water, saccharin sodium, sodium benzoate, and sorbitol solution. The product’s purple, clear bluish-red appearance and grape flavor fit the conventional presentation of an OTC pediatric-adjacent liquid, though the label’s age limits set boundaries around who should receive it.
OTC Labeling Still Depends on Clear Symptom Sorting
This label update, marked October 9, 2026, does not introduce a new mechanism or a new indication. It reinforces the older logic of combination cold therapy: suppress cough, reduce sneezing and rhinorrhea, and ease congestion with one oral liquid. For clinicians and pharmacists, the value lies in screening for MAOI use, cardiovascular disease, urinary obstruction, glaucoma, and chronic cough patterns before a patient reaches for an over-the-counter bottle.
For consumers, the more consequential detail is the stop rule. A cough that lingers, fever that appears, or symptoms that do not improve within a week should push the evaluation out of the OTC aisle and back into clinical care. The label is built around temporary relief, not diagnostic certainty, and persistent cough remains one of the clearest reasons not to continue self-treatment.